In This Story
Becton Dickinson and Company (BDX0.00%) has submitted its Form 10-Q filing for the quarterly period ended December 31, 2024.
The filing reports a 9.8% increase in revenues to $5.168 billion compared to the same period in the previous year. This growth was driven by volume increases, pricing, foreign currency impacts, and the acquisition of Advanced Patient Monitoring.
Net income for the quarter was $303 million, up from $281 million in the previous year. Basic earnings per share were reported at $1.05, with diluted earnings per share at $1.04.
The company reported operating income of $453 million, with total operating costs and expenses amounting to $4.715 billion. The increase in costs was attributed to higher selling and administrative expenses, research and development expenses, and integration, restructuring, and transaction expenses.
Cash provided by operating activities was $693 million, while cash used for investing activities was $204 million, primarily due to capital expenditures and maturities of investments. Financing activities used $1.928 billion, which included debt repayments and share repurchases.
Becton Dickinson announced its intention to separate its Biosciences and Diagnostic Solutions business by fiscal year 2026. The company plans to provide more details by the end of fiscal year 2025.
The filing also discusses various legal proceedings and regulatory matters, including product liability claims and compliance with the FDA's Consent Decree related to its infusion pump business.
The company highlighted potential risks impacting its operations, including macroeconomic factors, geopolitical developments, and regulatory changes.
Becton Dickinson continues to focus on its BD 2025 strategy, emphasizing growth, simplification, and empowerment to drive revenue and profit growth.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Becton Dickinson and Company quarterly 10-Q report dated February 6, 2025. To report an error, please email earnings@qz.com.